ClinicalTrials.Veeva

Menu

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing (genetics MM)

S

Siriraj Hospital

Status

Not yet enrolling

Conditions

Plasma Cell Disorder

Study type

Observational

Funder types

Other

Identifiers

NCT06330896
346/2566(IRB3)

Details and patient eligibility

About

The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:

  • genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing
  • genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients.
  • disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS.
  • correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients.

The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.

Enrollment

498 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis
  • Aged 18 years and older
  • Performed FISH and/or NGS testing
  • Has treatment follow up at least one year

Exclusion criteria

  • Patients with missing crucial data that renders them unanalyzable
  • Patients who refuse to participate in the study

Trial contacts and locations

0

Loading...

Central trial contact

Chutima Kunacheewa; Weerapat Owattanapanich

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems